ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1349
CHEMBL1349
Compound Name VALACYCLOVIR
ChEMBL Synonyms 256U87 HYDROCHLORIDE | VALTREX | Valacyclovir | VALACYCLOVIR HYDROCHLORIDE | VALACICLOVIR | ZELITREX
Max Phase 4 (Approved)
Trade Names VALACYCLOVIR HYDROCHLORIDE | VALTREX | ZELITREX
Molecular Formula C13H20N6O4

Additional synonyms for CHEMBL1349 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CC(C)[C@H](N)C(=O)OCCOCn1cnc2C(=O)N=C(N)Nc12
Standard InChI InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9- ...
Download InChI
Standard InChI Key HDOVUKNUBWVHOX-QMMMGPOBSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1349

Molecule Features

CHEMBL1349 compound icon
Drug Type:Natural Product-derived Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:Y Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Human herpesvirus 1 DNA polymerase inhibitor Human herpesvirus 1 DNA polymerase FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
AstrocytomaD001254EFO:0002499anaplastic astrocytoma2ClinicalTrials
GlioblastomaD005909EFO:0000519glioblastoma multiforme2ClinicalTrials
Herpes GenitalisD006558EFO:0007282genital herpes4DailyMed
DailyMed
DailyMed
ClinicalTrials
NeoplasmsD009369EFO:0000311cancer3ClinicalTrials
Psychotic DisordersD011618EFO:0005407psychosis2ClinicalTrials
ClinicalTrials
Waldenstrom MacroglobulinemiaD008258EFO:0002616macroglobulinemia2ClinicalTrials
ChickenpoxD002644EFO:0007204chickenpox4ClinicalTrials
DailyMed
DailyMed
DailyMed
SchizophreniaD012559EFO:0000692schizophrenia2ClinicalTrials
Bipolar DisorderD001714EFO:0000289bipolar disorder2ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm3ClinicalTrials
Herpes ZosterD006562EFO:0006510Herpes Zoster4ClinicalTrials
DailyMed
DailyMed
DailyMed
ClinicalTrials
Infectious MononucleosisD007244EFO:0007326infectious mononucleosis1ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000673prostate adenocarcinoma3ClinicalTrials
Encephalitis, JapaneseD004672EFO:0007332Japanese encephalitis3ClinicalTrials
Herpes LabialisD006560EFO:1001347Herpes Labialis4DailyMed
DailyMed
DailyMed
ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma3ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-CellD015451EFO:0000095chronic lymphocytic leukemia2ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma1ClinicalTrials
Hepatitis C, ChronicD019698EFO:0004220Chronic Hepatitis C infection2ClinicalTrials
Stomatitis, HerpeticD013283EFO:0007307Herpes simplex virus gingivostomatitis2ClinicalTrials
Cytomegalovirus InfectionsD003586EFO:0001062cytomegalovirus infection2ClinicalTrials
EpendymomaD004806EFO:1000028ependymoma1ClinicalTrials
Virus DiseasesD014777EFO:0000763viral disease4ATC
ClinicalTrials

Clinical Data

ClinicalTrials.gov VALACYCLOVIR
The Cochrane Collaboration VALACYCLOVIR

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1349. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL2360 Hypoxanthine-guanine phosphoribosyltransferase Homo sapiens 1.000
CHEMBL4338 Purine nucleoside phosphorylase Homo sapiens 1.000
CHEMBL1293237 Bloom syndrome protein Homo sapiens 0.973
CHEMBL2966 Adenosine deaminase Bos taurus 0.968

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL2360 Hypoxanthine-guanine phosphoribosyltransferase Homo sapiens 1.000
CHEMBL4338 Purine nucleoside phosphorylase Homo sapiens 1.000
CHEMBL2966 Adenosine deaminase Bos taurus 0.996
CHEMBL1293237 Bloom syndrome protein Homo sapiens 0.416
CHEMBL2605 Adenosine A2a receptor Cavia porcellus 0.241

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
324.3 324.1546 -0.8 7 151.14 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
9 3 0 10 5 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- 7.75 .42 -.09 2 23 0.44

Structural Alerts

There are 5 structural alerts for CHEMBL1349. To view alerts please click here.

Compound Cross References

ATC J - ANTIINFECTIVES FOR SYSTEMIC USE
J05 - ANTIVIRALS FOR SYSTEMIC USE
J05A - DIRECT ACTING ANTIVIRALS
J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB11 - valaciclovir

ChemSpider ChemSpider:HDOVUKNUBWVHOX-QMMMGPOBSA-N
DailyMed valacyclovir hydrochloride
PubChem SID: 29215498 SID: 56422581
Wikipedia Valaciclovir

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1349



ACToR 124832-26-4
BindingDB 50162073
Brenda 208584 208585 14482
ChEBI 35854
DrugBank DB00577
DrugCentral 2798
eMolecules 902639
EPA CompTox Dashboard DTXSID1023732
FDA SRS MZ1IW7Q79D
Guide to Pharmacology 4824
Human Metabolome Database HMDB0014716
IBM Patent System F02F1AE31AD427099AC796EF73C03E3E
LINCS LSM-5571
MolPort MolPort-002-885-872
Nikkaji J480.132F
PDBe TXC
PharmGKB PA451839
PubChem 60773
PubChem: Drugs of the Future 12014356
PubChem: Thomson Pharma 14801572 15940044 14850689 14850688 14874889 14777186
SureChEMBL SCHEMBL28644
ZINC ZINC000001530713

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/HDOVUKNUBWVHOX-QMMMGPOBSA-N spacer
spacer